31 results about "Tumor-Specific Antibody" patented technology

The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

The invention relates to PH-sensitive targeted LPNs (lipid poly-L-histidine hybrid nanoparticles) for encapsulating anti-tumor drugs. The LPNs comprise raw materials in percentage by mass as follows:50%-80% of PHIS (poly-histidine) and 20%-50% of lipid (including lipid-PEG), wherein the lipid PEG accounts for 1%-100% of the total mass of lipid. A hydrophobic core consists of PHIS, and the surfaceis modified with polyethylene glycol and tumor targeted peptide. The PEGylated lipid surface has the characteristics of good biocompatibility, high stability and long in-vivo circulation. A histidinecore can encapsulate the hydrophobic anti-cancer drugs under the neutral condition, histidine is protonized in the tumor microenvironment to mediate the carrier potential to change from negative to near neutral, intake and endocytosis of a carrier arepromoted, the carrier mediates the lysosome to escape after endocytosis, the drugs are released rapidly, tumor cells are effectively killed, and accordingly, the problems that the PEGylated nano-carrier endocytosis efficiency is low and cannot release the drugs in cells effectively after endocytosis are solved. The surface of the carrier can bemodified with a tumor-specific antibody or ligand, the tumor targeting property is further improved, and the therapeutic effect is improved.

The present invention discloses anti-DOTA chimeric antigen receptor-modified T cells and anti-tumor applications thereof, wherein the anti-DOTA chimeric antigen receptor comprises an extracellular domain formed by an anti-DOTA antibody light chain variable domain (VL) and an anti-DOTA antibody heavy chain variable domain (VH), the leader sequence is CD8[alpha] chain signal peptide, the DOTA single chain antibody is coupled to a CD8 hinge, the obtained hinge is coupled with the CD8 transmembrane domain, and the obtained material is coupled with the activation domain and the immunologic receptor tyrosine activation motif peptide CD3[zeta] domain of the co-stimulatory molecule CD137 (4-1BB). According to the present invention, when tumor cells are bound to tumor-specific antibody-conjugated DOTA, the anti-DOTA chimeric antigen receptor-modified T cells of the present invention can specially recognize and kill the tumor cells.

The invention discloses an extracorporeal circulation cancer cell purification system, which includes a probe pump for providing probes for cobalt ferrite-coupled tumor-specific antibodies, which are set on the channel of the extracorporeal circulation based on connecting pipelines, A blood pump providing circulation power and a magnetic separator with a built-in magnetic separation column, wherein the magnetic separator is located at the rear stage of the probe pump. The invention can flexibly capture CTCs in or in vivo and purify the blood, thus providing a brand-new approach for reducing the occurrence of malignant tumor metastasis.

The present invention provides a drug delivery system wherein a "parachute" structure is coupled to a therapeutic compound. The "parachute" structure comprises hydrophilic branched molecular fragments, or a cyclodextrin moiety, with a defined action diameter. The complex (a parachute structure coupled with a therapeutic compound) is either fixed at a cell membrane or delivered to a defined distance from the membrane within the cell. The membrane-anchoring/localizing effect of the parachute is achieved by hydrophilic structures linked with a branching unit of desired therapeutic compounds. Furthermore, the parachute structures can be connected by a spacer (e.g. beta-amino acids, gamma-amino butyric acid, or poly-amino acids) instead of directly binding to the therapeutic compound, so that the therapeutic compounds can be localized within the cells at a defined distance from the cell membrane. A spacer containing a breaking point can determine the time span, during which the drug exhibits its therapeutic activity. The hydrophilic residues can also carry signals for targeting the parachute-therapeutic complex to a defined tissue type. This can be mediated by an antibody which is specific for a tumor marker. Alternatively, a biotin can be attached at C6 position of the sugar and then react with an avidin-labeled tumor-specific antibody. The parachute function may also be achieved by other, more bulky hydrophilic structures such as oligosaccharides connected to the branching unit. Such sugar oligomers have specific attachment points to cell selecting, and therefore do not need additional molecular structures to target a specific tumor tissue. The use of the parachute structure gives the advantages of being able to localize a photosensitizer or chemotherapeutic drug at the site within a cell where it can destroy the tumor cell most effectively. This reduces the level of necessary systemic doses of the drugs, promotes drug excretion, and therefore considerably reduces side effects of the therapy.

The invention discloses a B cell vaccine based on Hepal-6 hepatoma cell autophagosome-DRibbles and a preparation method of the B cell vaccine. The invention firstly finds that the Hepal-6 hepatoma cell autophagosome-DRibbles used as a novel antigen carrier with an adjuvant function can be used for activating a B lymphocyte to generate a specific antibody and effectively present an antigen, and an immune mouse can induce a specific cell and humoral immune response. In addition, the Hepal-6 hepatoma cell autophagosome-DRibbles are firstly used for inducing a B cell to generate a tumor specificity antibody and effectively present a tumor antigen. The Hepal-6 hepatoma cell autophagosome-DRibbles are natural exocytosis components of a cell, and the vaccine based on the Hepal-6 hepatoma cell autophagosome-DRibbles can be used for reducing the possible harms to an organism on the basis of improving the immune response capacity, so that the vaccine is a novel antigen carrier with broad prospects.

Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors. Also disclosed are methods for detecting, localizing and imaging a solid tumor before or during a tumor resection surgery using the antibody-fluorophore conjugate.

The invention relates to a tumor specific antibody linked with LIGHT protein or fragments thereof, a combination comprising the same, a method for preventing and treating cancer and application thereof. The LIGHT-antibody and combination of the invention are applicable to preventing and treating primary and/or metastatic cancer and reducing, inhibiting and decreasing primary tumor growth and/or cancer metastasis.

The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.

The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.

Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.

The invention discloses an individual method for fast obtaining tumor specific antibodies. The method comprises the following steps of directly removing cancer cell or cancerous tissue and normal cellor normal tissue sharing antigens by normal cell or normal tissue antibodies with corresponding antibody phases in the body. The method does not perform large-scale scanning on the antigens in vitro.By using the method, 11 kinds of anti-HepG2 monoclonal antibodies are obtained. The monoclonal antibodies have the specific recognition on HepG2, and do not recognize or basically do not recognize HHcell. Meanwhile, compared with cancer cells with other tissue resources, the monoclonal antibodies have specific recognition on HePG2.

The invention discloses an MICA extracellular region mutant, a screening method thereof, an scFv-MICA fusion antibody, and a preparation method and application of the scFv-MICA fusion antibody. The MICA extracellular region mutant is mutated at the 24th site, the 33th site, the 69th site, the 112th site and the 126th site. The screening method comprises the following steps: constructing a mutant MICA bacteriophage library, expressing recombinant protein NKG2D-Fc, screening bacteriophage and the like. The scFv-MICA fusion antibody is formed by linking scFv and an MICA mutant through a flexiblepeptide. The preparation method comprises the following steps: constructing a recombinant gene of a fusion antibody, constructing a recombinant vector, transfecting competent cells, performing expressing and purifying, and the like. The MICA extracellular region mutant disclosed by the invention can be used for efficiently inducing the cytotoxic effect of NKG2D mediated NK cells; the fusion antibody constructed by the MICA extracellular region mutant and scFv can utilize a tumor specific antibody part to efficiently target tumor cells, and meanwhile, the high-affinity mutation MICA part can mediate NK cells and the like to effectively kill target cells.

Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.